Jonathan Hopper - Feb 17, 2023 Form 4 Insider Report for Vericel Corp (VCEL)

Role
Chief Medical Officer
Signature
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Stock symbol
VCEL
Transactions as of
Feb 17, 2023
Transactions value $
-$55,465
Form type
4
Date filed
2/22/2023, 07:57 PM
Previous filing
Feb 14, 2023
Next filing
Nov 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCEL Common Stock Options Exercise $0 +2.33K +4.63% $0.00 52.5K Feb 18, 2023 Direct F1, F2
transaction VCEL Common Stock Tax liability -$33K -1.11K -2.11% $29.82 51.4K Feb 18, 2023 Direct F2, F3
transaction VCEL Common Stock Options Exercise $0 +1.75K +3.4% $0.00 53.2K Feb 19, 2023 Direct F2, F4
transaction VCEL Common Stock Tax liability -$22.4K -752 -1.41% $29.82 52.4K Feb 19, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCEL Stock Option (Right to Buy) Award $0 +1.88K $0.00 1.88K Feb 17, 2023 Common Stock 1.88K $29.82 Direct F5
transaction VCEL Stock Option (Right to Buy) Award $0 +28.1K $0.00 28.1K Feb 17, 2023 Common Stock 28.1K $29.82 Direct F5
transaction VCEL Restricted Stock Unit Award $0 +12K $0.00 12K Feb 17, 2023 Common Stock 12K Direct F6, F7, F8
transaction VCEL Restricted Stock Unit Options Exercise -2.33K -25% 6.98K Feb 18, 2023 Common Stock 2.33K Direct F1, F6, F8, F9
transaction VCEL Restricted Stock Unit Options Exercise -1.75K -33.33% 3.5K Feb 19, 2023 Common Stock 1.75K Direct F4, F6, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026.
F2 These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3 These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units.
F4 The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2024 and February 19, 2025.
F5 These options shall begin vesting on February 17, 2023 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
F6 Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F7 These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 17, 2024. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively.
F8 No expiration date for this type of award.
F9 The Fair Market Value of the vested derivative securities is $29.82 per share.